MedPath

浙江三生蔓迪药业有限公司

Ownership
-
Established
1997-10-27
Employees
-
Market Cap
-
Website
https://www.3s-md.com/aboutus

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

76

NMPA:76

Drug Approvals

Ubidecarenone Injection

Product Name
辅酶Q10注射液
Approval Number
国药准字H33020904
Approval Date
Sep 13, 2024
NMPA

Nifedipine Tablets

Product Name
硝苯地平片
Approval Number
国药准字H33020910
Approval Date
Sep 13, 2024
NMPA

Nitrendipine Tablets

Product Name
尼群地平片
Approval Number
国药准字H33020907
Approval Date
Sep 13, 2024
NMPA

Ibuprofen Tablets

Product Name
布洛芬片
Approval Number
国药准字H33021147
Approval Date
Sep 10, 2024
NMPA

Furazolidone

Product Name
呋喃唑酮
Approval Number
国药准字H33020914
Approval Date
Sep 10, 2024
NMPA

Irsogladine Maleate Tablets

Product Name
科玛诺
Approval Number
国药准字H19990064
Approval Date
Sep 9, 2024
NMPA

Anastrozole Tablets

Product Name
瑞斯意
Approval Number
国药准字H20010532
Approval Date
Sep 9, 2024
NMPA

Rosiglitazone Hydrochloride Tablets

Product Name
宜力喜
Approval Number
国药准字H20041409
Approval Date
Sep 6, 2024
NMPA

Polyinosinic-Polycytidylic Acid Injection

Product Name
聚肌胞注射液
Approval Number
国药准字H20003550
Approval Date
Sep 5, 2024
NMPA

Rosiglitazone Hydrochloride Tablets

Product Name
宜力喜
Approval Number
国药准字H20041408
Approval Date
Sep 5, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.